Skip to Content

Lucassin Approval Status

FDA Approved: No
Brand name: Lucassin
Generic name: terlipressin
Dosage form: for Injection
Company: Mallinckrodt plc
Treatment for: Hepatorenal Syndrome

Lucassin (terlipressin) is a synthetic vasopressin analogue in development for the treatment of hepatorenal syndrome (HRS) Type 1.

Development Status and FDA Approval Process for Lucassin

DateArticle
Jul 28, 2016First Patient Enrolled in Mallinckrodt Phase 3 Terlipressin Trial
Mar 30, 2010Ikaria Acquires New Drug Application for Lucassin
Jun 12, 2009FDA Accepts Final Section of NDA Filing for Lucassin

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide